Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Quarterly Report · 10-Q

Neumora Therapeutics, Inc.

NMRANASDAQEQUITYCurrent

Quarterly Report

Filed Aug 14, 2026Accepted Aug 14, 2026, 7:23 AM EDTCIK 1885522Accession 0001193125-26-350370
Share

Company context

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

Current securities

Recent company filings

  1. 4 filingAug 21, 2026
  2. 4 filingAug 21, 2026
  3. 4 filingAug 21, 2026
  4. 144 filingAug 21, 2026
  5. 144 filingAug 20, 2026

As-filed source

Primary evidence